
This is the first time such an algorithm was validated in a large US claims database.

This is the first time such an algorithm was validated in a large US claims database.

Patients with rheumatoid arthritis are frequently encouraged to look at their lifestyle and make changes, such as exercising more frequently, following a balanced diet and maintaining a healthy weight. But what does a balanced diet actually mean? Test your knowledge of the impact of diet on rheumatoid arthritis with our diet quiz to be assured you know the answers to questions patients might ask.

Combining methotrexate with TNF inhibitors may only be worthwhile for rheumatoid arthritis patients who are seropositive, the results of a small study suggest.

Continuous low-dose glucocorticoid regimens are better than tapering for controlling disease activity in rheumatoid arthritis over a six-month period, show the results of the first double blind clinical trial to evaluate an oral glucocorticoid dose-tapering regimen with stable biological background therapy in rheumatoid arthritis.

Vascular stiffness―which is often the precursor to a major cardiovascular event―appears to be present in early rheumatoid arthritis, shows a new study published in the Annals of the Rheumatic Diseases.

A retrospective study published in The Lancet Rheumatology shows that the long-term use of hydroxychloroquine to treat rheumatoid arthritis patients may increase the risk of cardiovascular mortality.

Gilead expects topline results available from a pair of trials testing the new treatment in 2021.

Patients with rheumatoid arthritis are at increased risk for osteoporosis. This heightened risk of osteoporosis can be due to a combination of factors: inactivity due to the pain and loss of joint function associated with the disease, a direct the rheumatoid arthritis disease process, and their treatment for rheumatoid arthritis. In this quiz, test your knowledge on the risk of osteoporosis in rheumatoid arthritis and how it should be treated.

In an interview with Rheumatology Network, Dr. Beate Wieseler compares the effectiveness of biologic drugs used to treat rheumatoid arthritis after methotrexate fails.

The prior use of methotrexate for rheumatoid arthritis patients doesn't seem to be associated with an increased risk of developing fibrotic interstitial lung disease, a common and potentially deadly complication of RA.

Patients with rheumatoid arthritis have an increased risk of cardiovascular events and cardiovascular death. How much do you know about cardiovascular risk related to rheumatoid arthritis and its treatment?

In this week's news roundup from Rheumatology Network, we talk with Dr. Jeffrey Sparks, a rheumatologist with Brigham and Women’s Hospital in Boston who recently addressed the importance of an interdisciplinary and individualized approach in treating rheumatic disease patients who have interstitial lung disease, a condition that can lead to worsen morbidity and mortality. Learn more in this interview.

Researchers writing in RMD Open suggest that rheumatoid arthritis patients be assessed for the risk of gastrointestinal perforation before treatment with tocilizumab.

A treat-to-target strategy is recommended over a non-targeted approach for managing rheumatoid arthritis patients, regardless of the level of disease activity. But what should the target be and how should progress be monitored? Test your knowledge in this quiz.

The U.S. FDA has approved the sixth biosimilar to Humira, adalimumab-FKJP (Hulio), which will be available in the United States in 2023 for rheumatoid arthritis, psoriatic arthritis, psoriasis, juvenile arthritis and other conditions.

A new study shows that the JAK-inhibitor upadacitinib (Rinvoq, AbbVie) led to remission by 24 weeks in patients with moderately to severely active rheumatoid arthritis.

Methotrexate is considered first-line therapy for rheumatoid arthritis, but if this fails to control symptoms, it is time to consider a second-line therapy. TNF inhibitors and IL inhibitors are options, but which to choose? Learn more in this quiz.

Patients with rheumatic disease are at higher risk for skin cancer, gastrointestinal infectious, pulmonary disease, and hematologic conditions. A new study finds that taking low-dose methotrexate may lower the risk of developing these conditions.

Rheumatoid arthritis is not associated with an increased risk of death in patients hospitalized for pneumonia, unless it is uncontrolled, shows a new study.

Rheumatoid arthritis patients have nearly a double risk of atherosclerotic CVD, stroke, heart failure and atrial fibrillation, but they receive poorer primary and secondary preventive care than other high-risk patients. Learn more in this summary of a review published in Nature Reviews Rheumatology.

The mosquito-borne chikungunya virus can lead to symptoms of arthritis that are similar to rheumatoid arthritis. In this Q&A, we speak with the an expert who recently published a review article focusing on the commonalities between the two conditions.

Rheumatoid arthritis is not a life threatening condition per se, but it can have a dramatic impact on life expectancy. As a chronic systemic inflammatory condition, rheumatoid arthritis increases the risk of a number of other leading causes of death. Are you familiar with mortality risk in RA? Take this quiz.

In today's news roundup, we feature a discussion with Ben Nowell, Ph.D., director of Patient Centered Research for the Global Healthy Living Foundation, which five years ago launched ArthritisPower, a mobile app used in healthcare research. Learn more in this interview.

There are many treatments and strategies to address fatigue in rheumatoid arthritis (RA) patients, but no one approach works for all patients. In this slideshow, we highlight key takeaways from a recent review that highlights key strategies for treating fatigue in RA.

Rheumatoid arthritis patients receive treatment that is on par with that of a physician, shows a study based on patient-reported outcomes and disease activity. The study was recently reported at the EULAR annual meeting.